Skip to content

A Trial on Clinical Efficacy of 1% Versus 2% Lignocaine in Cough Suppression and Pain Relief in Patients Undergoing Flexible Bronchoscopy

A RCT ON CLINICAL EFFICACY OF 1% vs. 2% LIGNOCAINE IN COUGH SUPPRESSION AND PAIN RELIEF IN PATIENTS UNDERGOING FLEXIBLE BRONCHOSCOPY

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01955824
Enrollment
500
Registered
2013-10-08
Start date
2014-05-31
Completion date
2014-11-30
Last updated
2014-12-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Interstitial Lung Disease, Lung Cancer, Sarcoidosis, Tuberculosis

Keywords

bronchoscopy, lignocaine, cough

Brief summary

Flexible bronchoscopy is a common procedure performed by pulmonary physicians. The use of topical anesthesia, analgesia, and sedation during flexible bronchoscopy varies among physicians, institutions and geographic locations across the globe. Commonly used topical anesthetic agents before and during bronchoscopy include cocaine (4%),benzocaine (20%), tetracaine (1%), and lignocaine (1%-10%). Topical lignocaine is administered through the flexible bronchoscope in an attempt to reduce excessive coughing and patient discomfort. However, the optimal dosage and strength of topical lignocaine that should be used during fibreoptic bronchoscopy has long been a topic of controversy. In this study we compare the efficacy of 1% versus 2% lignocaine in controlling cough and pain in patients undergoing flexible bronchoscopy.

Interventions

DRUG1% lignocaine

Sponsors

Post Graduate Institute of Medical Education and Research, Chandigarh
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
12 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Consecutive patients undergoing flexible bronchoscopy * Hemodynamic stability

Exclusion criteria

* Patients receiving sedatives during the course of their treatment * Patients undergoing conventional TBNA and/or EBUS-TBNA who are likely to receive sedation * Patients with known hypersensitivity to lignocaine * Not willing to provide informed consent

Design outcomes

Primary

MeasureTime frameDescription
Cough suppression (by Operator and Patient)15 minutesCough will be rated on a visual analog scale (VAS) from 0 (no cough) to 100 mm (worst cough ever)
Pain control15 minutesPain will be assessed on Wong Baker Face rating scale

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 15, 2026